0.25Open0.25Pre Close31 Volume106 Open Interest2.50Strike Price775.00Turnover112.36%IV10.00%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.5581Delta0.5768Gamma9.09Leverage Ratio-0.0064Theta0.0007Rho5.07Eff Leverage0.0024Vega
Allogene Therapeutics Stock Discussion
07/11/2024 - 23:00
Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%
TRAVERSE Trial Highlights the Ability of CD70 Dagger® Te...
3.20+
No comment yet